Press Releases

 Sign up for email alerts here

 

Date Title and Summary Additional Formats
Toggle Summary Genocea to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
CAMBRIDGE, Mass. , July 06, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the upcoming Cantor Fitzgerald 2 nd Annual
View HTML
Toggle Summary Genocea Appoints Ron Cooper to Board of Directors
CAMBRIDGE, Mass. , June 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Ron Cooper has joined its board of directors, effective immediately. Mr.
View HTML
Toggle Summary Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016
- Presentation of GEN-003 12-Month Data Featured in ASM Press Briefing - - Phase 2 GEN-004 Results Highlight Potential for Future Development of Vaccine for Pneumococcal Disease - CAMBRIDGE, Mass. , June 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical
View HTML
Toggle Summary Genocea Appoints Dr. John E. Bishop as Senior Vice President of Pharmaceutical Sciences
CAMBRIDGE, Mass. , May 23, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that John E. Bishop , Ph.D. has joined the company as senior vice president of pharmaceutical sciences.
View HTML
Toggle Summary Genocea to Present at the 2016 UBS Global Healthcare Conference
CAMBRIDGE, Mass. , May 17, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the upcoming 2016 UBS Global Healthcare Conference on
View HTML
Toggle Summary Genocea Reports First Quarter 2016 Financial Results
 - Positive 12-month efficacy data for GEN-003 for genital herpes strengthens value proposition - - Multiple 2016 clinical milestones for GEN-003 anticipated - CAMBRIDGE, Mass. , May 05, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T
View HTML
Toggle Summary Genocea to Host First Quarter 2016 Financial Results Conference Call & Webcast on May 5, 2016
CAMBRIDGE, Mass. , April 28, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, May 5, 2016 at 9:00 a.m.
View HTML
Toggle Summary Genocea Congratulates Dr. George Siber, 2016 Albert B. Sabin Gold Medal Award Recipient
Genocea director recognized for outstanding contributions to immunology and infectious disease research through vaccine development
View HTML
Toggle Summary Genocea to Present at the 15th Annual Needham Healthcare Conference
CAMBRIDGE, Mass. , April 06, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the upcoming 15 th Annual Needham Healthcare
View HTML
Toggle Summary Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing
- Consistent efficacy across potential Phase 3 clinical trial endpoints - - Once-yearly or less frequent maintenance dosing expected - - Company to host conference call at 9 a.m. ET today - CAMBRIDGE, Mass. , March 31, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a
View HTML
Toggle Summary Genocea to Present at the Cowen and Company 36th Annual Health Care Conference
CAMBRIDGE, Mass. , Feb. 29, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark , president and chief executive officer, will present a company overview at the
View HTML
Toggle Summary Genocea Reports Fourth Quarter and Year-End 2015 Financial Results
- Multiple 2016 clinical milestones for GEN-003 for genital herpes anticipated - - Cancer vaccine strategy targeting generation of first clinical candidate in 2017 - CAMBRIDGE, Mass. , Feb. 11, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing
View HTML
Toggle Summary Genocea to Host Fourth Quarter and Year End 2015 Financial Results Conference Call & Webcast on February 11, 2016
CAMBRIDGE, Mass. , Feb. 04, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, February 11, 2016 at 9:00 a.m.
View HTML
Toggle Summary Genocea to Present at 2016 BIO CEO & Investor Conference
CAMBRIDGE, Mass. , Feb. 01, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark , president and chief executive officer, will present a company overview at the
View HTML
Toggle Summary Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003
- Top-line viral shedding data expected in mid-2016 - - Six month clinical efficacy data against potential Phase 3 endpoints expected in 2H 2016 - CAMBRIDGE, Mass. , Jan. 29, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed
View HTML